EUVIMEDEUVIMED entdecken
Open Access

In vivo engineering tumor cells to a universal “all-in-one” cancer vaccine with full antigen spectrum

Wanting Wang iD, Yue Huang, Junshi Zhang, Yuan Wang, Zekun Yu, Fanmeng Zhang, Huihui Zhang iD, Ruiqi Zhang, Runbo Zhong iD, Hua Zhong, Lu Zhang iD, Chen Liu und 4 weitere

Science Advances · 10.07.2026 · 12 (28)

DOI: 10.1126/sciadv.aee5201 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, erschienen am 10.07.2026. Verfasst von Wanting Wang und 15 weiteren Autor:innen. Beteiligte Einrichtung: Sheng Yushou Center of Cell Biology and Immunology, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, China. Hauptthemen laut MEDLINE: Cancer Vaccines, Antigens, Neoplasm, Neoplasms. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer vaccines offer a promising strategy to initiate de novo T cell responses or enhance existing ones, either functioning independently or synergizing with T cell–modulating therapeutics to reduce tumor burden. The clinical development of cancer vaccines faces challenges such as limited antigen coverage, insufficient antigen presentation, immune suppressive microenvironment, and the availability of personalized vaccines. In this study, we developed a universal “all-in-one” cancer cell–derived vaccine (UniCVac) with comprehensive antigen spectrum coverage by programming tumor cells into antigen-presenting cells (APCs) through the codelivery of CIITA, NLRC5, CD80, and IL-2. This reprogramming mimics the professional APC phenotype, providing simultaneous HLA-I and HLA-II antigen presentation, costimulation, and T cell proliferation signals. These tumor-derived UniCVac can directly activate both CD4 + and CD8 + T cells in vitro, independent of APCs. In addition, their costimulation and T cell growth-stimulating capabilities result in superior CD4 + and CD8 + T cell activation and proliferation comparable to traditional APCs, with enhanced PI3K-AKT pathways activation. Single-cell transcriptome analysis confirmed the similarity in cellular subtypes between UniCVac-activated and traditional APC-activated T cells. In mouse models, the UniCVac vaccination reprogramed the tumor microenvironment from immunosuppressive to immune-permissive, induced robust CD4 + and CD8 + T cell expansion in both preventive and therapeutic tumor models, and achieved complete tumor regression in vivo. Our approach provides a platform for the development of universal cancer vaccines with full antigen spectrum coverage and the ability to directly activate both CD4 + and CD8 + T cells, offering potential combinatorial opportunities with existing T cell–based immunotherapies against cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cancer VaccinesAntigens, NeoplasmNeoplasmsAnimalsHumansMiceAntigen-Presenting CellsCD8-Positive T-LymphocytesLymphocyte ActivationCell Line, TumorCD4-Positive T-LymphocytesAntigen PresentationFemaleTumor Microenvironment

Substanzen

Cancer VaccinesAntigens, Neoplasm

Autor:innen und Institutionen

  • Sheng Yushou Center of Cell Biology and Immunology, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, China.
  • Department of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Cellular and Molecular Medicine, School of life sciences, University of Bristol, Bristol, UK.
  • Department of mathematics and statistics, Northeastern University at Qinhuangdao, Qinhuangdao, China.
  • Department of Biomedical Sciences, University College London, London, UK.

ORCID-Profile: Wanting Wang, Huihui Zhang, Runbo Zhong, Lu Zhang, Xuanming Yang

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Wang, W., Huang, Y., Zhang, J., Wang, Y., Yu, Z., Zhang, F., Zhang, H., Zhang, R., Zhong, R., Zhong, H., Zhang, L., Liu, C., Shen, C., Li, Z., Wang, M., & Yang, X. (2026). In vivo engineering tumor cells to a universal “all-in-one” cancer vaccine with full antigen spectrum. Science Advances, 12(28). https://doi.org/10.1126/sciadv.aee5201

Vancouver

Wang W, Huang Y, Zhang J, Wang Y, Yu Z, Zhang F, et al. In vivo engineering tumor cells to a universal “all-in-one” cancer vaccine with full antigen spectrum. Science Advances. 2026;12(28). doi:10.1126/sciadv.aee5201

BibTeX
@article{Wang2026,
  author = {Wang, Wanting and Huang, Yue and Zhang, Junshi and Wang, Yuan and Yu, Zekun and Zhang, Fanmeng and Zhang, Huihui and Zhang, Ruiqi and Zhong, Runbo and Zhong, Hua and Zhang, Lu and Liu, Chen and Shen, Chenchen and Li, Zhaoyu and Wang, Mei and Yang, Xuanming},
  title = {In vivo engineering tumor cells to a universal “all-in-one” cancer vaccine with full antigen spectrum},
  journal = {Science Advances},
  year = {2026},
  volume = {12},
  number = {28},
  doi = {10.1126/sciadv.aee5201}
}
Kostenlos starten →